WBB Securities Analyst Steve Brozak says one of the biotechnology stocks he is recommending is Cytori Therapeutics Inc. (USA) (CYTX). He says the company’s latest product, which he expects to be marketed in the near future, transcends biotechnology.
“Cytori’s device extracts stem cells from a patient’s fat, or adipose cells,” Brozak says. “Candidly, it is something where we see this as being the first practical application of stem cells in regenerative medicine that we think will hit the markets in short order.”
FOR MORE INFORMATION ON THIS INTERVIEW CLICK HERE.
Brozak says Cytori’s device is used to draw and process a patient’s stem cells, but also includes a biologic process because the cells are used on the same patient to solve a medical issue.
“They’re testing these cells right now for use in patients that have severe burns. As a matter of fact, Cytori was awarded a BARDA contract to research and develop their technologies in burns and wound healing,” Brozak says. “They’ve been used commercially overseas for breast reconstruction in women who have had breast surgery for oncology purposes. They’ve been used for closing and healing tough-to-treat wounds because these cells obviously lend themselves to adhere and promote healing on open tissue, and we think that’s an exciting area.”
Progenitor Stem Cell Product from Capricor is Key to Longevity Drug Infusion Therapy: An Exclusive Interview with Dr. Linda Marbon
August 14, 2017
Seelos Therapeutics, Inc. (NASDAQ:SEEL) is Developing Blockbuster Drug Therapies
October 02, 2020
Tyson Foods, Inc. (TSN) Developing Integrated Production in China to Overcome Food Safety Concerns
April 30, 2014
Citigroup Inc (C) to Gain Investor Interest with Dividend Boost and Developing Markets Growth
January 30, 2015
Visa Inc (NYSE:V) Plays to the Demand for Prepaid Cards in Developing Countries
March 17, 2016
